Head to Head Comparison: CytomX Therapeutics (NASDAQ:CTMX) and Aclaris Therapeutics (ACRS)

CytomX Therapeutics (NASDAQ: CTMX) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.

Volatility and Risk

How to Become a New Pot Stock Millionaire

CytomX Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.

Profitability

This table compares CytomX Therapeutics and Aclaris Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CytomX Therapeutics -60.17% -71.42% -13.12%
Aclaris Therapeutics N/A -35.25% -33.17%

Valuation and Earnings

This table compares CytomX Therapeutics and Aclaris Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CytomX Therapeutics $71.62 million 15.05 -$43.09 million ($1.16) -24.07
Aclaris Therapeutics $1.68 million 306.24 -$68.52 million ($2.50) -6.66

CytomX Therapeutics has higher revenue and earnings than Aclaris Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for CytomX Therapeutics and Aclaris Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytomX Therapeutics 0 2 8 0 2.80
Aclaris Therapeutics 0 0 5 0 3.00

CytomX Therapeutics presently has a consensus target price of $40.17, indicating a potential upside of 43.86%. Aclaris Therapeutics has a consensus target price of $46.00, indicating a potential upside of 176.28%. Given Aclaris Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than CytomX Therapeutics.

Insider & Institutional Ownership

78.1% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 92.2% of Aclaris Therapeutics shares are held by institutional investors. 8.0% of CytomX Therapeutics shares are held by insiders. Comparatively, 16.3% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Aclaris Therapeutics beats CytomX Therapeutics on 9 of the 14 factors compared between the two stocks.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company’s drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply